Gene panel model predictive of outcome in patients with prostate cancer

OMICS A Journal of Integrative Biology

Volumn 17, Issue 8, 2013, Pages 407-413

  Rabiau, Nadège ^a,b,c   Dantal, Yann ^c   Guy, Laurent ^b,d   Ngollo, Marjolaine ^a,b   Dagdemir, Aslihan ^a,b   Kemeny, Jean Louis ^d   Terris, Benoît ^e   Vieillefond, Annick ^e   Boiteux, Jean Paul ^b,d   Bignon, Yves Jean ^a,b   Bernard Gallon, Dominique ^a,b  

^a CENTRE JEAN PERRIN   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c Soluscience SA Biopôle Clermont Limagne ^*  (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BRCA1 PROTEIN; BRCA2 PROTEIN; EPHRIN RECEPTOR B2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLUTATHIONE TRANSFERASE P1; INTERLEUKIN 18; MUCIN 1; PROTEIN BCL 2; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RIBONUCLEASE L; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION; GENE PANEL MODEL; GENETIC MODEL; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM;

EID: 84881075242     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2012.0124     Document Type: Article

References (55)

1. Adjakly M, Bosviel R, Rabiau N, et al. (2011). DNA methylation and soy phytoestrogens: Quantitative study in DU-145 and PC-3 human prostate cancer cell lines. Epigenomics 3, 795- 803.
2. Arbab IA, Looi CY, Abdul AB, et al. (2012). Dentatin induces apoptosis in prostate cancer cells via Bcl-2, Bcl-xL, survivin downregulation, caspase-9, - 3/7 activation, and NF-kappaB inhibition. Evid Based Complement Alternat Med 2012, 856029.
3. Bismar TA, Demichelis F, Riva A, et al. (2006). Defining aggressive prostate cancer using a 12-gene model. Neoplasia 8, 59-68.
4. Blute ML, Bergstralh EJ, Iocca A, Scherer B, and Zincke H. (2001). Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 165, 119-125.
5. Brawley OW. (2012). Prostate cancer epidemiology in the United States. World J Urol 30, 195-200.
6. Cheville JC, Karnes RJ, Therneau TM, et al. (2008). Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol 26, 3930-3936.
7. Clapp RW, Jacobs MM, and Loechler EL. (2008). Environmental and occupational causes of cancer: New evidence 2005-2007. Rev Environ Health 23, 1-37. (Pubitemid 351644506)
8. Colonna M, Danzon A, Delafosse P, et al. (2008). Cancer prevalence in France: Time trend, situation in 2002 and extrapolation to 2012. Eur J Cancer 44, 115-122. (Pubitemid 350256948)
9. Cozzi PJ, Wang J, Delprado W, et al. (2005). MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis 22, 565-573. (Pubitemid 43234641)
10. Dabir PD, Ottosen P, Hoyer S, and Hamilton-Dutoit S. (2012). Comparative analysis of three- and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma. Diagn Pathol 7, 81.
11. Dwivedi S, Goel A, Natu SM, Mandhani A, Khattri S, and Pant KK. (2011). Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: A prospective study. Asian Pac J Cancer Prev 12, 1843-1848.
12. Ferlay J, Parkin DM, and Steliarova-Foucher E. (2010). Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46, 765-781.
13. Fink L, Seeger W, Ermert L, et al. (1998). Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med 4, 1329- 1333. (Pubitemid 28512117)
14. Garbar C, Mascaux C, and Wespes E. (2008). Expression of MUC1 and sialyl-Tn in benign prostatic glands, high-grade prostate intraepithelial neoplasia and malignant prostatic glands: A preliminary study. Anal Quant Cytol Histol 30, 71- 77. (Pubitemid 351501866)
15. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, and Gerald WL. (2004). Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113, 913-923. (Pubitemid 38544150)
16. Hodge KK, McNeal JE, Terri, MK, and Stamey TA. (1989). Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142, 71-74; discussion 74-75.
17. Huang SP, Huang LC, Ting WC, et al. (2009). Prognostic significance of prostate cancer susceptibility variants on prostatespecific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 18, 3068-3074.
18. Humphrey PA. (2004). Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 17, 292-306. (Pubitemid 41646608)
19. Idikio HA. (2011). Galectin-3 and Beclin1/Atg6 genes in human cancers: Using cDNA tissue panel, qRT-PCR, and logistic regression model to identify cancer cell biomarkers. PLoS One 6, e26150.
20. Jin W, Wu DD, Zhang X, Irwin DM, and Zhang YP. (2012). Positive selection on the gene RNASEL: Correlation between patterns of evolution and function. Mol Biol Evol 29, 3161- 3168.
21. Kawamoto K, Okino ST, Place RF, et al. (2007). Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res 13, 2541-2548. (Pubitemid 46788019)
22. Kheirandish P, and Chinegwundoh F. (2011). Ethnic differences in prostate cancer. Br J Cancer 105, 481-485.
23. Kittles RA, Baffoe-Bonnie AB, Moses TY, et al. (2006). A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet 43, 507-511. (Pubitemid 43927325)
24. Knudsen BS, and Vasioukhin V. (2010). Mechanisms of prostate cancer initiation and progression. Adv Cancer Res 109, 1-50.
25. Kosari F, Munz JM, Savci-Heijink CD, et al. (2008). Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res 14, 1734-1743. (Pubitemid 351469458)
26. Kumaresan K, Kakkar N, Verma A, Mandal AK, Singh SK, and Joshi K. (2010). Diagnostic utility of alpha-methylacyl CoA racemase (P504S) & HMWCK in morphologically difficult prostate cancer. Diagn Pathol 5, 83.
27. Latil A, Bieche I, Vidaud D, et al. (2001). Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61, 1919-1926. (Pubitemid 32692008)
28. Lau KM, LaSpina M, Long J, and Ho SM. (2000). Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res 60, 3175- 3182. (Pubitemid 30407914)
29. Lee WH, Morton RA, Epstein JI, et al. (1994). Cytidine methylation of regulatory sequences near the pi-class glutathione Stransferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 91, 11733-11737. (Pubitemid 24356419)
30. Li LC, Chui R, Nakajima K, Oh BR, Au HC, and Dahiya R. (2000). Frequent methylation of estrogen receptor in prostate cancer: Correlation with tumor progression. Cancer Res 60, 702-706. (Pubitemid 30094570)
31. Li J, Zhang ZH, Yin CJ, et al. (2012). Effect of surgical procedures on prostate tumor gene expression profiles. Asian J Androl 14, 708-714.
32. Lossos IS, Czerwinski DK, Alizadeh AA, et al. (2004). Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350, 1828-1837. (Pubitemid 38917249)
33. Mahapatra S, Klee EW, Young CY, et al. (2012). Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 18, 2882-2895.
34. Mazzolini R, Dopeso H, Mateo-Lozano S, et al. (2012). Brush border myosin Ia has tumor suppressor activity in the intestine. Proc Natl Acad Sci USA 109, 1530-1535.
35. Mesko B, Poliska S, Szegedi A, et al. (2010). Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. BMC Med Genomics 3, 15.
36. Meyer MS, Penney KL, Stark JR, et al. (2010). Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis 31, 1597-1603.
37. Murthy VS, Garza MA, Almario DA, et al. (2011). Using a family history intervention to improve cancer risk perception in a black community. J Genet Couns 20, 639-649.
38. Nakamura Y, McNamara K, and Sasano H. (2013). Estrogen receptor expression and its relevant signaling pathway in prostate cancer: A target of therapy. Curr Mol Pharmacol Jan. 8 [Epub ahead of print].
39. Rabiau N, Dechelotte P, Adjakly M, et al. (2011). BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: Correlation between RT-qPCR and immunohistochemical detection. Oncol Rep 26, 695-702.
40. Rabiau N, Dechelotte P, Guy L, et al. (2009). Immunohistochemical staining of mucin 1 in prostate tissues. In Vivo 23, 203-207.
41. Rajabi H, Ahmad R, Jin C, et al. (2012). MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. Prostate 72, 1659-1668.
42. Ramaswamy S, Ross KN, Lander ES, and Golub TR. (2003). A molecular signature of metastasis in primary solid tumors. Nat Genet 33, 49-54. (Pubitemid 36068681)
43. Reibenwein J, Pils D, Horak P, et al. (2007). Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate 67, 427-432. (Pubitemid 46341084)
44. Roobol MJ, Haese A, and Bjartell A. (2011). Tumour markers in prostate cancer III: Biomarkers in urine. Acta Oncol 50, 85-89.
45. Ross RW, Galsky MD, Scher HI, et al. (2012). A whole-blood RNA transcript-based prognostic model in men with castrationresistant prostate cancer: A prospective study. Lancet Oncol 13, 1105-1113.
46. Scarpelli M, Mazzucchelli R, Barbisan F, et al. (2012). Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase. Int J Immunopathol Pharmacol 25, 67-74.
47. Schobesberger M, Baltzer A, Oberli A, et al. (2008). Gene expression variation between distinct areas of breast cancer measured from paraffin-embedded tissue cores. BMC Cancer 8, 343.
48. Singh D, Febbo PG, Ross K, et al. (2002). Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1, 203- 209. (Pubitemid 41039166)
49. Steinbach D, Schramm A, Eggert A, et al. (2006). Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res 12, 2434-2441.
50. Trpkov K, Bartczak-McKay J, and Yilmaz A. (2009). Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens. Am J Clin Pathol 132, 211-220.
51. van de Vijver MJ, He YD, van't Veer LJ, et al. (2002). A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347, 1999-2009. (Pubitemid 35461656)
52. Van Neste L, Bigley J, Toll A, et al. (2012). A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection. BMC Urol 12, 16.
53. Vardi A, Bosviel R, Rabiau N, et al. (2010). Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells. In Vivo 24, 393-400.
54. Walker CL. (2011). Epigenomic reprogramming of the developing reproductive tract and disease susceptibility in adulthood. Birth Defects Res A Clin Mol Teratol 91, 666-671.
55. Walton TJ, Li G, McCulloch TA, et al. (2009). Quantitative RTPCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue. Prostate 69, 810-819.